References
- United Nations Office on Drugs and Crime. The World Drug Report 2021, Booklet 2 Global Overview: Drug Demand/Drug Supply. https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_2.pdf Feb, 2021.
- Moeller, M. R.; Steinmeyer, S.; Kraemer, T. Determination of Drugs of Abuse in Blood. J. Chromatogr. B. 1998, 713, 91–109. DOI: 10.1016/S0378-4347(97)00573-2.
- Dinis-Oliveira, R. J.; Carvalho, F.; Duarte, J. A.; Remião, F.; Marques, A.; Santos, A.; Magalhães, T. Collection of Biological Samples in Forensic Toxicology. Toxicol. Mech. Methods. 2010, 20(7), 363–414. DOI: 10.3109/15376516.2010.497976.
- Bogusz, M.; Aderjan, R.; Schmitt, G.; Nadler, E.; Neureither, B. The Determination of Drugs of Abuse in Whole Blood by Means of FPIA and EMIT-Dau Immunoassays — a Comparative Study. Forensic. Sci. Int. 1990, 48, 27–37. DOI: 10.1016/0379-0738(90)90269-5.
- Fisher, J. Immunoassay Drug Screen Results: Easy to Get, Hard to Interpret. Clin. toxicol. 1998, 36(1–2), 115–116. DOI: 10.3109/15563659809162598.
- Datta, P. Immunoassay Design for Screening of Drugs of Abuse Second Edi. In Critical Issues in Alcohol and Drugs of Abuse Testing, Dasgupta, A., Ed. Elsevier Inc.: New York, 2019; pp. 121–128.
- American Academy of Forensic Sciences (AAFS). ASB Standard 113, Standard for Identification Criteria in Forensic Toxicology. 1st Edition 2020. http://www.asbstandardsboard.org/wpcontent/uploads/2020/01/113_Std_Ballot01.pdf (accessed May 7, 2021).
- Scientific Working Group for Forensic Toxicology (SWGTOX). Standard Practices for Method Validation in Forensic Toxicology. 2013. https://academic.oup.com/jat/article/37/7/452/765476 (accessed Jan 24, 2021).
- Lebeau, M. A. ANSI/ASB Standard 036 for Method Validation in Forensic Toxicology Has Replaced Swgtox’s Version. J. Anal. Toxicol. 2020, 44(4), 414. DOI: 10.1093/jat/bkz115.
- Busardò, F.; Pacifici, R.; Pichini, S. Mass Spectrometry Vs. Immunoassay in Clinical and Forensic Toxicology: Qui Modus in Rebus Est? Clin. Chem. Lab. Med. 2017, 55(10). DOI: 10.1515/cclm-2017-0418.
- Lappas, N. T.; Lappas, C. M. Forensic Toxicology: Principles and Concepts. Elsevier Inc.: New York, 2016.
- RANDOX. Toxicology Solutions. https://www.randoxtoxicology.com/wp-content/uploads/2020/01/LT193TOXToxicology-Solutions-SEP19-LQ.pdf(accessed May 5, 2021).
- Turkish Republic Ministry of Interior. General Diractorate of Security, Turkey Drug Report: Trends and Developments 2020. http://www.narkotik.pol.tr/narkolog-projesi-2020-raporu (accessed June 3, 2021).
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report: Trends and Developments, 2021. https://www.emcdda.europa.eu/system/files/publications/13838/TDAT21001ENN.pdf (accessed Feb 20, 2021).
- Republic of Turkey, Ministry of Interior, Narcotic Police Department. http://www.narkotik.pol.tr/kurumlar/narkotik.pol.tr/TUB%C4%B0M/2021-Turkiye-Uyusturucu-Raporu.pdf
- Kirschbaum, K. M.; Musshoff, F.; Schmithausen, R.; Stockhausen, S.; Madea, B. Optimization and Validation of CEDIA Drugs of Abuse Immunoassay Tests in Serum on Hitachi 912. Forensic. Sci. Int. 2011, 212(1–3), 252–255. DOI: 10.1016/j.forsciint.2011.06.029.
- Pelletti, G.; Garagnani, M.; Rossi, F.; Roffi, R.; Barone, R.; Pelotti, S. Optimization of Cloned Enzyme Donor Immunoassay Cut-Offs for Drugs of Abuse in Whole Blood of Drivers Involved in Road Accidents. Forensic. Sci. Int. 2019, 294, 27–33. DOI: 10.1016/j.forsciint.2018.10.023.
- McLaughlin, P.; Pounder, D.; Maskell, P.; Osselton, D. Real-Time Near-Body Drug Screening During Autopsy I: Use of the Randox Biochip Drugs of Abuse DOA I and DOA II Immunoassays. Forensic. Toxicol. 2013, 31(1), 113–118. DOI: 10.1007/s11419-012-0149-2.
- McLaughlin, P.; Maskell, P. D.; Pounder, D.; Osselton, D. Use of the Randox Evidence Investigator Immunoassay System for Near-Body Drug Screening During Post-Mortem Examination in 261 Forensic Cases. Forensic. Sci. Int. 2019, 294, 211–215. DOI: 10.1016/j.forsciint.2018.11.018.
- Castaneto, M. S.; Desrosiers, N. A.; Ellefsen, K., Anizan, S.; Martin, T.M.; Klette, K.L; Huestis, M.A. Method Validation of the Biochip Array Technology for Synthetic Cannabinoids Detection in Urine. Bioanalysis. 2014, 6(21), 2919–2930.
- Kahl, K. W.; Seither, J. Z.; Reidy, L. J. LC-MS-MS Vs ELISA: Validation of a Comprehensive Urine Toxicology Screen by LC-MS-MS and a Comparison of 100 Forensic Specimens. J. Anal. Toxicol. 2019, 43(9), 734–745. DOI: 10.1093/jat/bkz066.
- Marin, S. J.; Merrell, M.; McMillin, G. A. Drugs of Abuse Detection in Meconium: A Comparison Between ELISA and Biochip Microarray. J. Anal. Toxicol. 2011, 35(1), 40–45. DOI: 10.1093/anatox/35.1.40.